Related Experiment Video
Updated: Jul 31, 2026
06:34
Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides (CHIPS)
Published on: June 20, 2014
Indoline derivatives as 5-HT(2C) receptor agonists
J M Bentley1, D R Adams, D Bebbington
1Vernalis Research Ltd, Oakdene Court, 613 Reading Road, Winnersh, Wokingham, Berkshire RG41 5UA, UK. j.bentley@vernalis.com
Bioorganic & Medicinal Chemistry Letters
|April 15, 2004
Summary
Researchers developed novel compounds targeting serotonin 5-HT(2C) receptors to combat obesity. Some compounds effectively reduced food intake in rat models, showing promise for weight management therapies.
Area of Science:
- Medicinal Chemistry
- Neuropharmacology
- Drug Discovery
Background:
- Obesity is a complex metabolic disorder with limited effective long-term treatments.
- Serotonin 5-HT(2C) receptors are implicated in appetite regulation and represent a potential therapeutic target for weight management.
Purpose of the Study:
- To synthesize and evaluate a series of novel 1-(1-indolinyl)-2-propylamine derivatives as potential 5-HT(2C) receptor agonists.
- To assess the efficacy of these compounds in modulating food intake.
Main Methods:
- Synthesis of novel indole precursors and 1-(1-indolinyl)-2-propylamine derivatives.
- In vitro evaluation of compound affinity for serotonin 5-HT(2) receptor subtypes using radioligand binding assays.
- In vivo assessment of the effects of compounds on food intake in a rat model following oral administration.
Main Results:
- A series of 1-(1-indolinyl)-2-propylamines were successfully synthesized.
- Functional efficacy and radioligand binding data at 5-HT(2) receptor subtypes were obtained for all synthesized compounds.
- Several compounds demonstrated significant reduction in food intake in rats after oral administration, indicating 5-HT(2C) receptor agonist activity.
Conclusions:
- The synthesized 1-(1-indolinyl)-2-propylamine derivatives show potential as 5-HT(2C) receptor agonists.
- These compounds represent promising candidates for further development as anti-obesity agents.
More Related Videos
Related Concept Videos
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...